{
    "clinical_study": {
        "@rank": "87445", 
        "arm_group": [
            {
                "arm_group_label": "Arm A - Veliparib Monotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this arm will be dosed with Veliparib continuous dosing."
            }, 
            {
                "arm_group_label": "Arm B - Veliparib in Combination with Carboplatin & Paclitaxel", 
                "arm_group_type": "Experimental", 
                "description": "Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy."
            }, 
            {
                "arm_group_label": "Arm C  Veliparib in Combination with Modified FOLFIRI", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an extension study to evaluate the safety of Veliparib monotherapy or in combination\n      with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI)\n      in subjects with solid tumors."
        }, 
        "brief_title": "A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Ovarian Cancer", 
            "Colon Cancer", 
            "Lung Cancer", 
            "Gastric Cancer", 
            "Solid Tumors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colonic Neoplasms", 
                "Lung Neoplasms", 
                "Stomach Neoplasms", 
                "Ovarian Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have confirmed solid malignancy that is metastatic, and standard curative\n             measures or other therapy that may provide clinical benefit do not exist or are no\n             longer effective.\n\n          -  For Veliparib monotherapy (must have tumor with defects in DNA repair mechanisms\n             (BRCA mutation or high grade ovarian cancer or solid tumors for combination therapy.\n\n          -  If the subject has known brain metastases must have clinically controlled neurologic\n             symptoms, defined as surgical excision and/or radiation therapy followed by 21 days\n             of stable neurologic function and no evidence of Central Nervous System (CNS) disease\n             progression as determined by comparing a computed tomography (CT) scan or magnetic\n             resonance imaging (MRI) scan performed during screening to a prior scan performed at\n             least 4 weeks earlier and provided that the subject is asymptomatic, has no evidence\n             of cavitation or hemorrhage, and does not require corticosteroids (must have\n             discontinued steroids at least 3 months prior to study drug administration).\n\n          -  Subject must have adequate bone marrow, renal and hepatic function per local\n             laboratory reference range.\n\n        Exclusion Criteria:\n\n          -  Subject has a clinically significant and uncontrolled major medical condition(s)\n             including but not limited to:\n\n          -  Uncontrolled seizure disorder, including focal or generalized seizure within the last\n             12 months;\n\n          -  Uncontrolled nausea/vomiting/diarrhea;\n\n          -  Active uncontrolled infection;\n\n          -  Symptomatic congestive heart failure;\n\n          -  Unstable angina pectoris or cardiac arrhythmia;\n\n          -  Psychiatric illness/social situation that would limit compliance with study\n             requirements;\n\n          -  Any medical condition, which in the opinion of the study investigator, places the\n             subject at an unacceptably high risk for toxicities.\n\n          -  Subjects who have hypersensitivity to Carboplatin, Paclitaxel or Cremophor should be\n             excluded from arm B.\n\n          -  Subject has received any of the following anti-cancer therapies 21 days prior to the\n             first dose of study drug or a biologic agent for anti-neoplastic intent within 30\n             days prior to the first dose of study drug.\n\n          -  Subject who requires parenteral nutrition, tube feeding or has evidence of a partial\n             bowel obstruction or perforation within 28 days prior to study drug.\n\n          -  The subject has had another active malignancy within the past 3 years except for any\n             cancer in situ that the Principal Investigator considers to be cured."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033551", 
            "org_study_id": "M14-144", 
            "secondary_id": "2013-003137-16"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A - Veliparib Monotherapy", 
                    "Arm B - Veliparib in Combination with Carboplatin & Paclitaxel", 
                    "Arm C  Veliparib in Combination with Modified FOLFIRI"
                ], 
                "intervention_name": "Veliparib", 
                "intervention_type": "Drug", 
                "other_name": "ABT-888"
            }, 
            {
                "arm_group_label": "Arm B - Veliparib in Combination with Carboplatin & Paclitaxel", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B - Veliparib in Combination with Carboplatin & Paclitaxel", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }, 
            {
                "arm_group_label": "Arm C  Veliparib in Combination with Modified FOLFIRI", 
                "description": "combination of Fluorouracil, leucovorin and irinotecan", 
                "intervention_name": "FOLFIRI", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Solid Tumors", 
            "Gastric Cancer", 
            "Ovarian Cancer", 
            "PARP Inhibitor", 
            "Colon Cancer", 
            "Breast Cancer", 
            "Lung Cancer"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Site Reference ID/Investigator# 117416"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Site Reference ID/Investigator# 117415"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningn", 
                        "country": "Netherlands", 
                        "zip": "9713 GZ"
                    }, 
                    "name": "Site Reference ID/Investigator# 117337"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229 HX"
                    }, 
                    "name": "Site Reference ID/Investigator# 117338"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Site Reference ID/Investigator# 117451"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Stacie  Shepherd, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Measured up to 30 days after the last dose of study drug."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033551"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Radiographic evaluation at Screening and every 6-9 weeks until the final visit, up to 18 months."
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months after the subject is registered off study up to 2 years post discontinuation or until date of death from any cause, whichever comes first."
            }, 
            {
                "measure": "Time to Disease Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "Assessed at each visit up to 18 months after the last subject has enrolled in the study."
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Radiographic evaluation starting from the first day of study drug until documented progression or date of death, whichever comes first, until the subject is registered off study."
            }, 
            {
                "description": "Hematology, Chemistry, Urinalysis", 
                "measure": "Clinical Laboratory Tests", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 18 months."
            }, 
            {
                "measure": "Electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 18 months."
            }, 
            {
                "description": "A computerized tomography scan to document the size of the tumor.", 
                "measure": "Tumor Assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 18 months."
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}